Propeller Health and Boehringer Ingelheim Pharmaceuticals are launching a first-of-its-kind commercial partnership that aims to use digital health tools and services to help people living with COPD and asthma better manage their disease.
Under the terms of the partnership, people living with COPD and asthma, who are being treated with a Boehringer Ingelheim prescription medication approved for use in the company’s Respimat inhaler, will have the opportunity to enroll at select US health systems in a new program that is designed to determine how Propeller’s novel health technology tool for the Respimat inhaler impacts adherence rates and patient engagement.
In March 2015, the FDA granted 510(k) clearance to market Propeller’s health technology platform in association with the Respimat inhaler. Propeller uses a combination of inhaler sensors, apps, analytics, personal feedback and education. The platform passively tracks how and when each patient uses their inhaled medications and can send alerts to patients and their caregivers. Propeller creates a custom view for each patient, allowing them to better understand the impact and management of their disease in daily life.
“We are excited to work with Boehringer Ingelheim to bring Propeller to people with asthma and COPD at health systems across the US. Together, we believe that digital tools can complement the use of respiratory medications and encourage more appropriate and effective management of chronic respiratory disease,” said David Van Sickle, CEO of Propeller.
“As a committed partner to the respiratory community for nearly a century, Boehringer Ingelheim is proud to embark on this industry-leading partnership with Propeller with the goal of improving the care of people living with COPD and asthma,” said Ruchin Kansal, executive director and head, Business Innovation, Boehringer Ingelheim Pharmaceuticals Inc.
